GlaxoSmithKline

The Lupus Research Alliance launched the DREAM platform, a knowledge-exchange tool for researchers and lupus patients, completing the Lupus Nexus program aimed at accelerating precision medicine in lupus.

Antibiotics like nitrofurantoin, TMP-SMX, and fosfomycin are first-line treatments for UTIs. Iterum Therapeutics' ORLYNVAH, an oral antibiotic, received FDA approval for treating UTIs caused by specific bacteria, marking a significant advancement. Future UTI treatments focus on overcoming antibiotic resistance with novel therapies, including GSK’s Gepotidacin and Inmunotek’s Uromune, promising a revolution in UTI management.

Moderna's Q3 COVID-19 vaccine sales exceeded expectations at $1.8B, but full-year guidance remains unchanged, suggesting a potential decline in Q4. mResvia, Moderna's RSV vaccine, generated $10M in revenue, significantly below projections. Moderna plans to cut R&D expenses by 20% and prioritize investments in new vaccines and rare disease drugs.

Ionis Pharmaceuticals (IONS) reported a narrower-than-expected Q3 2024 loss of 95 cents per share, with total revenues of $134 million, beating estimates. The company's shares have declined 22.9% YTD. Ionis receives royalties from Biogen for Spinraza and co-markets Qalsody with Biogen. Wainua, co-marketed with AstraZeneca, was approved in the U.S. and the UK, generating $30 million in milestone payments. Commercial revenues were $76 million, missing estimates. Ionis maintained its 2024 financial guidance, expecting total revenues over $575 million and an adjusted operating loss of less than $475 million.

The Lupus Research Alliance launched the DREAM, a knowledge-exchange platform with secure data-sharing for researchers and research engagement for lupus patients, completing the Lupus Nexus program aimed at accelerating precision medicine in lupus.

At the 7th China International Import Expo, Johnson & Johnson launched INVEGA HAFYERA for schizophrenia, Pfizer showcased dermatology solutions, and GSK announced Phase III studies for Bepirovirsen, a potential hepatitis B treatment, and a public welfare project for systemic lupus erythematosus.

DelveInsight's 'Severe Asthma Pipeline Insight 2024' highlights 40+ companies developing 50+ therapies, including promising candidates like KN-002, BAT2606, CM326, and others. Key companies include Kinaset Therapeutics, GlaxoSmithKline, Sanofi, and AstraZeneca. Recent milestones include positive phase III results for GSK's depemokimab and phase IIb data for Sanofi's rilzabrutinib. The report covers global pipeline, therapeutic assessments, and key insights on severe asthma treatment.

DelveInsight's 'Tetanus Pipeline Insight 2024' report highlights 20+ companies developing 20+ pipeline tetanus drugs, including GC 3111A, KD-370, and TNM 002. Key companies like G C Pharma and KM Biologics are advancing therapies, with promising candidates in various clinical phases. The report also notes a study suggesting tetanus vaccination may reduce Parkinson's disease occurrence.

Beam Therapeutics reported a patient death in a Phase I/II trial for BEAM-101, attributing it to the preconditioning regimen, not the treatment. The FDA allowed the trial to continue without changes. Researchers seek less toxic alternatives to busulfan, crucial in cell and gene therapy protocols.